Anavex Life Sciences Corp. (AVXL) financial statements (2022 and earlier)
Company profile
| Business Address |
51 W 52ND STREET, NEW YORK, NY 10019-6163 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| SIC | 8731 - Commercial Physical and Biological Research (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 TTM | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 47 | 29 | 22 | 23 | 27 | 9 | ||
| Cash and cash equivalents | 47 | 29 | 22 | 23 | 27 | 9 | ||
| Receivables | 7 | 5 | 3 | |||||
| Prepaid expense | 0 | 0 | 1 | 0 | 0 | |||
| Other undisclosed current assets | 1 | 0 | 0 | 0 | ||||
| Total current assets: | 54 | 35 | 25 | 24 | 28 | 9 | ||
| Noncurrent Assets | ||||||||
| Deposits noncurrent assets | 0 | 0 | 0 | |||||
| Total noncurrent assets: | 0 | 0 | 0 | |||||
| TOTAL ASSETS: | 54 | 35 | 25 | 24 | 28 | 9 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 8 | 7 | 5 | 4 | 4 | 3 | ||
| Accounts payable | 4 | 4 | 4 | |||||
| Accrued liabilities | 4 | 3 | 2 | |||||
| Other undisclosed accounts payable and accrued liabilities | 4 | 4 | 3 | |||||
| Other undisclosed current liabilities | 0 | |||||||
| Total current liabilities: | 8 | 7 | 5 | 4 | 4 | 3 | ||
| Noncurrent Liabilities | ||||||||
| Total liabilities: | 8 | 7 | 5 | 4 | 4 | 3 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 46 | 27 | 20 | 20 | 24 | 6 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 214 | 187 | 154 | 129 | 116 | 84 | ||
| Accumulated deficit | (168) | (160) | (133) | (109) | (91) | (78) | ||
| Total stockholders' equity: | 46 | 27 | 20 | 20 | 24 | 6 | ||
| TOTAL LIABILITIES AND EQUITY: | 54 | 35 | 25 | 24 | 28 | 9 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 TTM | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | ||
|---|---|---|---|---|---|---|---|
| Operating expenses | (33) | (31) | (29) | (19) | (16) | (16) | |
| Operating loss: | (33) | (31) | (29) | (19) | (16) | (16) | |
| Nonoperating income | 5 | 5 | 3 | 2 | 2 | 1 | |
| Interest and debt expense | 0 | (0) | 0 | ||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (0) | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (27) | (26) | (26) | (17) | (13) | (15) | |
| Other undisclosed income (loss) from continuing operations before income taxes | 0 | (0) | |||||
| Loss from continuing operations before income taxes: | (27) | (26) | (26) | (17) | (13) | (15) | |
| Income tax expense | (0) | (0) | (0) | (0) | (0) | (0) | |
| Net loss available to common stockholders, diluted: | (28) | (26) | (26) | (17) | (13) | (15) | |
Comprehensive Income ($ in millions)
| 12/31/2020 TTM | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (28) | (26) | (26) | (17) | (13) | (15) | |
| Comprehensive loss, net of tax, attributable to parent: | (28) | (26) | (26) | (17) | (13) | (15) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.